IMC Chicago
OCUL icon

IMC Chicago’s Ocular Therapeutix OCUL Stock Holding History

IMC Chicago’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-97,202
Closed -$926K – 5890
2025
Q4 		$1.18M Buy
+97,202
New +$1.18M ﹤0.01% 2851
2025
Q3 		– Sell
-207,765
Closed -$2.48M – 3797
2025
Q2 		$1.93M Buy
+207,765
New +$1.63M ﹤0.01% 2030

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IMC Chicago's OCUL Position: Q1 2026 in Review

IMC Chicago sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 97,202 shares — an estimated $926K sold.

IMC Chicago first reported a position in OCUL in Q2 2025 and held it in 2 quarters. The position peaked at $1.93M in Q2 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • IMC Chicago reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • IMC Chicago sold 97,202 Ocular Therapeutix shares in Q1 2026, an estimated $926K.
  • IMC Chicago first reported a position in Ocular Therapeutix in Q2 2025 and held it in 2 quarters.
  • IMC Chicago's Ocular Therapeutix position peaked at $1.93M in Q2 2025.
  • 271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.